RxDoctor Payments Data

Jacqueline Kelly, MD

Radiation Oncology · Lincoln, NENPI 1730507971

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 262 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 6.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,452, more than ten times the $50 reported in 2019. Among radiation oncology clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,849in general payments, 2019–2025

Across 262 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$293
  • AstraZeneca$284
  • Visionrt, Inc.$265
  • Merck$255
  • Novartis$251
  • Eisai Inc.$199
  • plus $3K from 54 others

What the payments were for

  • Food & beverage$4,849100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,849 in reported general payments places this provider in the 90th percentile of 32 radiation oncology providers in Nebraska.

See all radiation oncology providers in Nebraska

Medicare billing

Part B allowed, 2024
$784,330
Medicare patients
404
Services billed
5,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lidocaine Hcl ViscousLidocaine Hcl18$289
Ondansetron Hcl11$23

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →